Back to Search
Start Over
Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.
- Source :
-
The American journal of medicine [Am J Med] 2020 Oct; Vol. 133 (10), pp. 1187-1194. Date of Electronic Publication: 2020 Apr 06. - Publication Year :
- 2020
-
Abstract
- Background: Digoxin reduces the risk of heart failure hospitalization in patients with heart failure with reduced ejection fraction. Less is known about this association in patients with heart failure with preserved ejection fraction (HFpEF), the examination of which was the objective of the current study.<br />Methods: In the Medicare-linked OPTIMIZE-HF registry, 7374 patients hospitalized for HF had ejection fraction ≥50% and were not receiving digoxin prior to admission. Of these, 5675 had a heart rate ≥50 beats per minute, an estimated glomerular filtration rate ≥30 mL/min/1.73 m <superscript>2</superscript> or did not receive inpatient dialysis, and digoxin was initiated in 524 of these patients. Using propensity scores for digoxin initiation, calculated for each of the 5675 patients, we assembled a matched cohort of 513 pairs of patients initiated and not initiated on digoxin, balanced on 58 baseline characteristics (mean age, 80 years; 66% women; 8% African American). Hazard ratios (HRs) and 95% confidence intervals (CIs) for outcomes associated with digoxin initiation were estimated in the matched cohort.<br />Results: Among the 1026 matched patients with HFpEF, 30-day heart failure readmission occurred in 6% and 9% of patients initiated and not initiated on digoxin, respectively (HR 0.70; 95% CI, 0.45-1.10; P = .124). HRs (95% CIs) for 30-day all-cause readmission and all-cause mortality associated with digoxin initiation were 0.95 (0.73-1.23; P = .689) and 0.93 (0.55-1.56; P = .773), respectively. Digoxin initiation had no association with 6-year outcomes.<br />Conclusion: Digoxin initiation prior to hospital discharge was not associated with 30-day or 6-year outcomes in older hospitalized patients with HFpEF.<br /> (Published by Elsevier Inc.)
- Subjects :
- Adrenergic beta-Antagonists therapeutic use
Aged
Aged, 80 and over
Angiotensin Receptor Antagonists therapeutic use
Angiotensin-Converting Enzyme Inhibitors therapeutic use
Anti-Arrhythmia Agents therapeutic use
Anticoagulants therapeutic use
Atrial Fibrillation drug therapy
Atrial Fibrillation epidemiology
Cause of Death
Female
Heart Failure epidemiology
Heart Failure physiopathology
Hospitalization
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Male
Mineralocorticoid Receptor Antagonists therapeutic use
Platelet Aggregation Inhibitors therapeutic use
Propensity Score
Proportional Hazards Models
Registries
Sodium Potassium Chloride Symporter Inhibitors therapeutic use
Warfarin therapeutic use
Cardiotonic Agents therapeutic use
Digoxin therapeutic use
Heart Failure drug therapy
Mortality
Patient Readmission statistics & numerical data
Stroke Volume
Subjects
Details
- Language :
- English
- ISSN :
- 1555-7162
- Volume :
- 133
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- The American journal of medicine
- Publication Type :
- Academic Journal
- Accession number :
- 32272101
- Full Text :
- https://doi.org/10.1016/j.amjmed.2020.02.040